RFA-AI-20-035: Martin Delaney Collaboratories for HIV Cure Research (UM1 Clinical Trial Not Allowed)
Slots: Only one application per institution is allowed to either this FOA or RFA-AI-20-036 (see below).
Internal Deadline: August 21, 2020, noon PT
LOI: November 6, 2020
External Deadline: December 7, 2020
Award Information: Type: Cooperative Agreement
Estimated Number of Awards: 1
Anticipated Amount: Application budgets are limited to $3.5M in direct costs per year and need to reflect the actual needs of the proposed project. The total project period must be 5 years.
Who May Serve as PI: Standard NIH eligibility requirements.
Process for Limited Submissions: PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://research.usc.edu/usc-grants/.
Materials to submit include:
(1) Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 1-page limit will be excluded from review.
(2) CV – (5 pages maximum)
Purpose: The objective of this FOA is to support highly collaborative and synergistic research programs focused on the development of specific strategies to achieve either a sustained viral remission or complete eradication of persistent HIV reservoirs, through academic, industry, government, and community partnerships. The awardee will be required to communicate and collaborate with other awards made under this and the companion Martin Delaney Collaboratory for Pediatric HIV Cure Research program. The proposed research should be innovative and must include a combination of basic, clinical, and applied research. The research program must be divided into three, interconnected areas of research focus: 1) Basic Research, 2) Control of Rebound, and 3) Eradication/Inactivation.
Examples of areas of research interest include, but are not limited to:
- Identification and characterization of the cellular, tissue, and anatomical reservoirs of HIV that persist in individuals treated with effective ART regimens and serve as the source of rebound viremia following cessation of therapy.
- Development of physiologically relevant assays for quantifying rebound-competent HIV reservoirs and identifying biomarkers for predicting viral rebound.
- Characterization of rebound-competent HIV proviruses, their clonal expansion, and variables affecting their control or viral rebound after cessation of ART.
- Studies of the mechanisms of post-treatment control in individuals that have undergone treatment interruption.
- Development and analysis of therapeutic strategies that are hypothesized to lead to sustained, durable control (either immunologic or therapeutic) of viral rebound following the cessation of ART.
- Identification and preclinical testing of innovative strategies and combination approaches to reduce the size of the rebound-competent reservoir, towards an ultimate goal of permanently eradicating or inactivating rebound-competent virus to achieve a “classical” cure (no remaining rebound-competent virus).
Applicants are encouraged to include research to characterize and/or target HIV reservoirs in all tissues, including the central nervous system. Applications that include characterization of reservoirs in the central nervous system and/or cells of the myeloid lineage and the impact of interventions on viral rebound in this compartment and cell types will be considered for co-funding by NIMH, NIDA, and NINDS. Applications that include characterization of reservoirs in the gastrointestinal tract, male genital tract, kidney, and/or adipose tissue will be considered for co-funding by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). In addition, applications that include research evaluating the effects of addictive substances on HIV persistence at key reservoir sites will be considered for co-funding by NIDA.
The research proposed is expected to push the boundaries of what is currently feasible. It is expected that aspects of the research plan necessarily will include high-risk research and implementation of cutting-edge technology. Development of combination treatment strategies and/or gene-based therapies would be particularly suitable for this FOA.
Budgetary Requirements: This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Visit our Institutionally Limited Submission webpage for more updates and other announcements.